“…The DMARDs administered within the first year in these 76 patients were as The baseline clinical manifestations and variables included gender, age, disease duration from onset to entry, morning stiffness, DMARDs, glucocorticoid, DAS28-CRP, CRP (measured by latex turbidimetric immunosorbent assay; Daiichi Pure Chemicals, Fukuoka, Japan), matrix metalloproteinase 3 (MMP-3; measured by enzyme-linked immunosorbent assay [ELISA]; the cut-off value was 59.7 ng/mL for females and 121.0 ng/mL for males; Daiichi Pure Chemicals), anti-cyclic citrullinated peptide antibodies (ACPA) (measured by ELISA, with a cut-off value of 4.5 U/mL; DIASTAT Anti-CCP; Axis-Shield, Dundee, UK), rheumatoid factor (RF) (measured by latex-enhanced immunonephelometric assay, with a cut-off value of 14 IU/mL; Dade Behring, Marburg, Germany), MRI synovitis, MRI bone edema, MRI bone erosion, and plain radiographs. All variables were examined on the same day, as described previously [17,[24][25][26][27].…”